Cargando…

Empagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient With Type 2 Diabetes Mellitus

Euglycemic diabetic ketoacidosis (euDKA) is an uncommon condition, which is characterized by an elevated anion gap metabolic acidosis with ketonemia/ketonuria, in the presence of normal blood glucose levels. Common risk factors for the development of this condition include pregnancy, prolonged fasti...

Descripción completa

Detalles Bibliográficos
Autores principales: Chauhan, Sukhjinder, Manov, AndreyI, Dhillon, Gundip S, Shah, Pinak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9934848/
https://www.ncbi.nlm.nih.gov/pubmed/36819400
http://dx.doi.org/10.7759/cureus.33892
_version_ 1784889955170910208
author Chauhan, Sukhjinder
Manov, AndreyI
Dhillon, Gundip S
Shah, Pinak
author_facet Chauhan, Sukhjinder
Manov, AndreyI
Dhillon, Gundip S
Shah, Pinak
author_sort Chauhan, Sukhjinder
collection PubMed
description Euglycemic diabetic ketoacidosis (euDKA) is an uncommon condition, which is characterized by an elevated anion gap metabolic acidosis with ketonemia/ketonuria, in the presence of normal blood glucose levels. Common risk factors for the development of this condition include pregnancy, prolonged fasting, acute pancreatitis, and bariatric surgery. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors have been identified as a rare cause of euDKA. A recent literature review on PubMed found only 86 case reports of euDKA secondary to SGLT inhibitors published in the medical literature up to December 2022. Here, we present the case of a 43-year-old man who was taking empagliflozin, an SGLT-2 inhibitor. The patient was found to have euDKA, which was likely an adverse effect of his medication.
format Online
Article
Text
id pubmed-9934848
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-99348482023-02-17 Empagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient With Type 2 Diabetes Mellitus Chauhan, Sukhjinder Manov, AndreyI Dhillon, Gundip S Shah, Pinak Cureus Cardiology Euglycemic diabetic ketoacidosis (euDKA) is an uncommon condition, which is characterized by an elevated anion gap metabolic acidosis with ketonemia/ketonuria, in the presence of normal blood glucose levels. Common risk factors for the development of this condition include pregnancy, prolonged fasting, acute pancreatitis, and bariatric surgery. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors have been identified as a rare cause of euDKA. A recent literature review on PubMed found only 86 case reports of euDKA secondary to SGLT inhibitors published in the medical literature up to December 2022. Here, we present the case of a 43-year-old man who was taking empagliflozin, an SGLT-2 inhibitor. The patient was found to have euDKA, which was likely an adverse effect of his medication. Cureus 2023-01-17 /pmc/articles/PMC9934848/ /pubmed/36819400 http://dx.doi.org/10.7759/cureus.33892 Text en Copyright © 2023, Chauhan et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Cardiology
Chauhan, Sukhjinder
Manov, AndreyI
Dhillon, Gundip S
Shah, Pinak
Empagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient With Type 2 Diabetes Mellitus
title Empagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient With Type 2 Diabetes Mellitus
title_full Empagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient With Type 2 Diabetes Mellitus
title_fullStr Empagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient With Type 2 Diabetes Mellitus
title_full_unstemmed Empagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient With Type 2 Diabetes Mellitus
title_short Empagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient With Type 2 Diabetes Mellitus
title_sort empagliflozin-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus
topic Cardiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9934848/
https://www.ncbi.nlm.nih.gov/pubmed/36819400
http://dx.doi.org/10.7759/cureus.33892
work_keys_str_mv AT chauhansukhjinder empagliflozinassociatedeuglycemicdiabeticketoacidosisinapatientwithtype2diabetesmellitus
AT manovandreyi empagliflozinassociatedeuglycemicdiabeticketoacidosisinapatientwithtype2diabetesmellitus
AT dhillongundips empagliflozinassociatedeuglycemicdiabeticketoacidosisinapatientwithtype2diabetesmellitus
AT shahpinak empagliflozinassociatedeuglycemicdiabeticketoacidosisinapatientwithtype2diabetesmellitus